About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.295 +0.325 (+5.44%)

Streaming Delayed Price Updated: 1:53 PM EST, Dec 11, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Cybin Granted US Patent Covering Lead Proprietary Compound ↗

February 10, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Earnings Scheduled For February 10, 2022 ↗

February 10, 2022

Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.

Via Benzinga

Psychedelic Stock Gainers And Losers From February 9, 2022 ↗

February 09, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76

Via Benzinga

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th ↗

February 09, 2022

The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,...

Via Benzinga

Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders ↗

February 09, 2022

Psychedelics company Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated...

Via Benzinga

Cybin's Vision Strengthens Position In Emerging Wellness Trend ↗

January 28, 2022

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health...

Via Benzinga

Cybin Schedules Release of Q3 Results, Conference Call ↗

January 27, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today ↗

February 08, 2022

GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

February 07, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23

Via Benzinga

Cybin Marks 2021 Accomplishments, Eyes 'Transformative' 2022 ↗

February 07, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins ↗

February 07, 2022

This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE.

Via Benzinga

Psychedelic Stocks Finally In An Upswing ↗

February 06, 2022

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week.

Via Talk Markets

Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today ↗

February 04, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20

Via Benzinga

Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

February 03, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19

Via Benzinga

Mind Medicine, Allied Among Top Psychedelic Movers Of Today ↗

February 02, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17

Via Benzinga

Mindset Pharma, Allied Among Top Psychedelic Movers Of Today ↗

February 01, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69

Via Benzinga

Cybin's IRB-Approved Study Begins Enrollment This Year ↗

February 01, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics...

Via Benzinga

Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants ↗

January 31, 2022

Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants.

Via Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today ↗

January 31, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33

Via Benzinga

The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January ↗

January 30, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Psychedelic Stock Gainers And Losers From January 28, 2022 ↗

January 28, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

January 27, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

January 26, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today ↗

January 25, 2022

GAINERS: Mind Medicine (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 24, 2022 ↗

January 24, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD ↗

January 23, 2022

This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...

Via Talk Markets

Psychedelic Stock Gainers And Losers From January 21, 2022 ↗

January 21, 2022

GAINERS: GH Research (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 20, 2022 ↗

January 20, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

January 19, 2022

GAINERS: Revive Therapeutics (OTC:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 18, 2022 ↗

January 18, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Cybin Inc. Common Shares (NY:CYBN)

Headline News about Cybin Inc. Common Shares

Sections

Services

Contact Information

Follow Us